Literature DB >> 9095412

Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study.

P Tiberghien1, J Y Cahn, A Brion, E Deconinck, E Racadot, P Hervé, N Milpied, B Lioure, E Gluckman, P Bordigoni, W Jacob, Y Chiang, S Marcus, C Reynolds, D Longo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9095412     DOI： 10.1089/hum.1997.8.5-615

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  9 in total

Review 1.  Suicide-gene-Transduced donor T-cells for controlled graft-versus-host disease and graft-versus-tumor.

Authors:  Fabio Ciceri; Claudio Bordignon
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 2.  Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Authors:  Donald R Shaffer; Cliona M Rooney; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

Review 3.  Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.

Authors:  Kenzaburo Tani
Journal:  Int J Hematol       Date:  2016-06-11       Impact factor: 2.490

Review 4.  Contributions of gene marking to cell and gene therapies.

Authors:  Cecilia N Barese; Cynthia E Dunbar
Journal:  Hum Gene Ther       Date:  2011-05-05       Impact factor: 5.695

Review 5.  Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.

Authors:  Faroogh Marofi; Heshu Sulaiman Rahman; Zaid Mahdi Jaber Al-Obaidi; Abduladheem Turki Jalil; Walid Kamal Abdelbasset; Wanich Suksatan; Aleksei Evgenievich Dorofeev; Navid Shomali; Max Stanley Chartrand; Yashwant Pathak; Ali Hassanzadeh; Behzad Baradaran; Majid Ahmadi; Hossein Saeedi; Safa Tahmasebi; Mostafa Jarahian
Journal:  Stem Cell Res Ther       Date:  2021-08-20       Impact factor: 6.832

6.  Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.

Authors:  E Bôle-Richard; C Gamonet; J-M Certoux; I Idirene; F Larosa; E Deconinck; A-M Mosseley; P Tiberghien; C Borg; C Ferrand; M Deschamps
Journal:  Gene Ther       Date:  2016-05-12       Impact factor: 5.250

Review 7.  Future prospects for CD8+ regulatory T cells in immune tolerance.

Authors:  Léa Flippe; Séverine Bézie; Ignacio Anegon; Carole Guillonneau
Journal:  Immunol Rev       Date:  2019-10-08       Impact factor: 12.988

Review 8.  Pharmacologic Control of CAR T Cells.

Authors:  Benjamin Caulier; Jorrit M Enserink; Sébastien Wälchli
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 9.  Toxicity and management in CAR T-cell therapy.

Authors:  Challice L Bonifant; Hollie J Jackson; Renier J Brentjens; Kevin J Curran
Journal:  Mol Ther Oncolytics       Date:  2016-04-20       Impact factor: 7.200
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.